“This study reaffirms that the number of people with OSA is expected to dramatically increase,” said Carlos Nunez, MD, chief medical officer at Resmed and study co-author.

Are oral OSA medications a real threat to CPAP providers who have dedicated a lot of time and money to serving patients?

Medtrade exhibitor Inogen revealed second quarter revenue of $92.3 million, a year-over-year increase of 4.0%.

Medtrade exhibitor Resmed Inc. revealed a revenue increase of 10% to $1.3 billion for fourth quarter 2025.

Medtrade exhibitor Inogen has appointed Kevin P. Smith as general counsel and executive vice president.

Second quarter results for Medtrade exhibitor Philips yielded group sales of EUR $4.3 billion.